Recent Updates
Recently added Catalysts
PSNL Positive Sentiment

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Personalis, Inc. announced that it will present its NeXT Personal ctDNA test at the ESMO Congress 2026. The presentations will include two oral and two poster presentations, featuring a late-breaking oral presentation of data from the C-POST Phase 3 trial. The congress will take place from October 23-27 in Madrid, Spain.

Market Sentiment Analysis

POSITIVE FACTORS

  • Personalis will present at ESMO Congress 2026.
  • NeXT Personal data includes a late-breaking oral presentation.
  • The event showcases advancements in precision oncology.

Full Press Release Details

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3

Frequently Asked Questions

What is the NeXT Personal ctDNA test?

It is an ultrasensitive circulating tumor DNA test for precision oncology.

When will the ESMO Congress 2026 take place?

The congress will occur from October 23-27, 2026.

What presentations will Personalis give at ESMO?

Personalis will present two oral and two poster presentations.

What is the C-POST Phase 3 trial?

It is a trial related to the NeXT Personal ctDNA test data.

ShareAdd on Google
Tags: PSNL Personalis ESMO 2026 ctDNA C-POST Phase 3 precision oncology
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$213M liquidity · $9M/mo burn
~23 mo
Low dilution risk